I read the PMCPA Social Media Guidance 2026 with a notebook and a headache. As an ABPI Final Signatory and industry mentor I’m writing this not to frighten you, but to hand you a pragmatic playbook. Regulators (MHRA, ABPI, PMCPA) have sharpened their pencils. If you work in pharma, med-tech or healthcare comms, this affects your LinkedIn headline, your influencer deals and the way you ‘Like’ a post. I’ll walk you through the essentials—what changed, where teams trip up, and exactly what I’d do if I were auditing a profile right now.
Why this matters to you today
Your LinkedIn headline could be advertising. Fix it.
I’m not saying that to scare you—I’m saying it because it’s now written plainly in the PMCPA Social Media Guidance 2026. I audited a colleague’s profile and flagged their headline within five minutes. The lesson was simple: your CV is personal, your public profile isn’t. On LinkedIn, your role, headline, and even what you amplify can be treated as information in the public domain—and that changes the compliance risk for Pharmaceutical Companies and their employees.
The Social Media Guidance was revised and published by the PMCPA in February 2026, with a new structure, clearer Q&As, and links to real cases. It’s also co-created with the MHRA, the ABPI, and industry reps—so it reflects how regulators now think about algorithms, feeds, and “small” actions like likes and shares.
“Regulators are no longer playing catch-up; they’re writing the playbook.” — Dr Anzal Qurbain
The big shift in the PMCPA Guidance is that the grey areas are shrinking. Social media use must show transparency and clearly separate promotional from non-promotional content. That’s not a creativity killer—it’s a design brief. When you know the lines, you can create faster, safer, and with fewer last-minute takedowns.
-
Prevention beats clean-up: a headline tweak today can avoid a complaint tomorrow.
-
Algorithms are part of the risk: your engagement can spread content beyond your intent.
-
Clarity protects teams: clearer rules help employees post with confidence.
What happened — The headlines in plain English
PMCPA Social Media: your LinkedIn profile now “counts”
The new PMCPA Social Media Guidance 2026 makes it clear: a public LinkedIn profile is treated as information in the public domain. That means your headline and visible summary can be judged like any other public comms under the ABPI Code.
Practical example: Product Manager for [Brand] (Obesity) is a risk if it puts a POM next to an indication/benefit in the feed. A safer alternative is Product Manager in Obesity.
Likes, shares, comments = redistribution
Interacting with a post can push it to your network, so the Guidance treats engagement as dissemination. If the content wouldn’t be compliant for you to publish, it’s risky to amplify it—whether it’s from an employee, agency, or third party. This is why regular training is no longer optional.
“A ‘Like’ functions as an endorsement in the eyes of the Code; treat it accordingly.” — Dr Anzal Qurbain
Influencers: #Ad isn’t enough
For influencer work, disclosure must be unmistakable, and companies are expected to do due diligence (including checking past content). You’re still responsible if an influencer goes off-script—so tighter review and approval steps are becoming the norm.
Clinical Trial Recruitment: new regulator from 1 February 2026
From 1 February 2026, Clinical Trial Recruitment participant-facing materials move to HRA oversight. If recruitment materials have REC approval, they don’t need extra certification under Clause 8.3.
Hashtag Guidelines + signposting: neutral, targeted, click-first
Signposting is allowed, but the post must be neutral, identify the audience, and require an active click to reach product info (no autoplay in-feed). The Hashtag Guidelines also raise the bar: check hashtags, tagging, and mentions to avoid unintended promotion.
What the Panel was really saying — Three principles
When I read the guidance, I didn’t see “new rules” as much as three Social Media Principles the Panel will keep applying—especially on LinkedIn, where the feed blurs personal and corporate voices.
1) Perception equals promotion (and the Scope Of ABPI is wider than you think)
If a claim appears in someone’s feed and my name is tied to it—through a headline, a “Like”, a repost, or a comment—it can look like promotion. That’s true even if I meant it as networking.
The Scope Of ABPI matters here: the Code can apply to activity outside the UK if it’s targeted at or accessible by a UK audience. On global platforms, “not UK” is rarely a safe assumption.
“Context, not intent, is what regulators will judge in a feed.” — Dr Anzal Qurbain
2) Control is responsibility (editorial control = liability)
If my company contracts an influencer, agency, or partner and keeps editorial control (briefs, approvals, required wording), the Panel will treat the output as ours. Transparency has to be obvious, and #ad alone may not do the job if the relationship isn’t instantly clear.
-
Contracts should cover approvals, monitoring, and what happens to posts after campaigns.
-
Governance should assume “off-script” still lands back on the company.
3) Context matters: Signposting Information vs direct dissemination
Signposting Information is the safe harbour—but only if the social post itself stays neutral, identifies the audience (e.g., investors/media), and requires an active click to reach product detail. If the feed shows product claims (or autoplay does), it starts to look like direct dissemination.
Where teams get caught — Common patterns and traps
Types Of Activity: headlines that cross the line
The fastest way I see teams get caught is an over-zealous LinkedIn headline. If your job title names a POM and its indication or benefit, it can look like promotion in the public domain. A classic high-risk example is: Product Manager for [Brand] (Obesity). I push teams to keep product names out of headlines and use therapy-area wording instead.
Casual engagement becomes redistribution
Another common trap is treating “Like” as harmless. Under the 2026 guidance, liking, sharing, or commenting can be seen as re-publishing. If the post includes a medicine benefit claim, your engagement can count as dissemination. This is why regular training matters—companies are responsible for employee activity, not just official channels.
Influencer Partnerships: weak clauses and weak control
Relying on #ad alone is risky. Disclosure must be clear and prominent, and you need a real approval process. Due diligence is also expected before signing—history checks, past posts, and patterns of risky wording.
“I once saw a compliant-looking post become a problem because an influencer used a product name in the first line—small slip, big fallout.” — Dr Anzal Qurbain
Hashtag Guidelines: the feed is the risk
I’ve seen compliant copy undermined by a risky hashtag feed. The guidance is simple: check the hashtag feed before use. If it’s full of product claims, don’t join it.
Misinformation Management: ad-hoc replies that turn promotional
Without a policy, teams reply in public and accidentally create corrective advertising. Keep responses factual, non-promotional, and consistent—and remember: testimonial-style wording can imply a claim, and editorial control makes it your responsibility.
Do this instead — Practical checks and an actionable checklist
“If you can’t certify every public social post as compliant, don’t post it. Simple litmus test.” — Dr Anzal Qurbain
1) Public profile audit (do today)
I start with the most visible risk: my headline and “About”. Remove product names and any POM + indication pairing from summaries. Keep therapy-area wording broad, and place brand details deeper in “Experience” where someone must click/scroll.
2) Employee Training: “A Like is a republish”
I bake this into onboarding and quarterly refreshers: likes, shares, and even supportive comments can disseminate non-compliant claims. If we wouldn’t approve the post, we don’t interact with it.
3) Pharmacovigilance Responsibilities on LinkedIn
I treat comments as part of the channel. We monitor, capture, and report adverse events fast, and we signpost reporting methods in our page info and response templates (e.g., Report AEs via [company PV email/portal]).
4) Influencer Partnerships: fix the contract, not the caption
-
Disclosure: explicit, plain-language involvement (not just
#ad). -
Pre-approval: written right to review and approve posts before publishing.
-
Post-contract: deletion vs archiving, data retention, and what happens to reposts.
5) Hashtag hygiene + misinformation protocol
-
Check the hashtag feed before using it; avoid tags dominated by product claims.
-
For misinformation: contact privately first; correct publicly only if needed, staying non-promotional and linking to SPC sections or compliant disease awareness pages.
6) Clinical Trial Recruitment (regulatory date: 1 Feb 2026)
I route participant-facing recruitment materials to the HRA and ensure REC approval. If REC-approved, Clause 8.3 certification is not required.
Wild cards — Short scenarios and creative analogies
I use these “wild cards” in training because they feel like real LinkedIn moments. They’re also great prompts for role-play across compliance, comms, legal, and marketing.
Scenario 1: The ex-employee headline (Patient Support)
An ex-colleague updates their headline to: BrandX Lead | Patient Support in Obesity. The brand is a POM. Are we liable? Yes, potentially—if the profile is public, still linked to our company presence, and reads like promotion. Even though they’ve left, the content is still “in the public domain” and can be screenshotted, shared, and treated as dissemination.
Analogy: LinkedIn is a conference room
I tell teams to treat the social feed like a conference room where every offhand comment is broadcast on a banner in the foyer. A “Like” becomes a loudspeaker. A headline becomes signage. If you wouldn’t put it on the foyer banner, don’t put it in the feed.
Scenario 2: Influencer Partnerships after the contract ends
An influencer posts off-script two months after a campaign ends, adding a benefit claim we never approved. The 2026 guidance is clear: transparency must be immediate and unambiguous, and responsibility can follow you if payment or editorial control was involved—even after the contract period.
-
Build in deletion/archiving terms and a recall process.
-
Require preview and certification of posts where applicable.
-
Do due diligence: check past misuse before signing.
Scenario 3: Corporate Announcements meet algorithms
A neutral post signposts to investor news, but the link preview names the medicine. That’s not signposting anymore—it’s dissemination. Fix by controlling previews and keeping the post itself neutral.
“Think like an editor, not a marketer—control the words you can, plan for the ones you can’t.” — Dr Anzal Qurbain
Conclusion
If 2026 has a headline for LinkedIn, it’s this: your intent matters less than how it looks in the feed.
What happened
The updated PMCPA Guidance and wider Social Media Guidance make one thing clear: the “digital wild west” is over. Personal profiles, likes, shares, influencer content, and even signposting are now judged through the lens of Regulatory Compliance—especially where perception, claims control, and balance can shift in a single click.
What Panel was saying
The message I take from the direction of travel is simple: if your activity can reasonably be seen as promotion, you should treat it like promotion. That means tighter briefing quality, clearer boundaries, and fewer “it’ll probably be fine” moments.
Where teams get caught
Teams don’t usually fall down because they’re careless. They fall down because systems are vague: job titles that imply a claim, engagement that republishes someone else’s wording, influencer posts that drift off-script, or “neutral” signposts that accidentally do the selling in the caption.
Do this instead
Audit what the public sees first (headline, featured, recent activity). Control what you can control (claims, context, balance). Brief better so partners and employees know what “good” looks like before they post—not after a complaint.
“Turn compliance into creative advantage—don’t let rules become roadblocks.” — Dr Anzal Qurbain
Strong takeaway: The digital wild west is over—audit, control, and brief better. I’m Dr Anzal Qurbain, ABPI Final Signatory and industry mentor—here to help you turn guidance into practical habits that protect brands and people.
Turning cases into culture — AskAnzal.
TL;DR: PMCPA’s 2026 guidance tightens the rules: personal LinkedIn profiles count, likes are redistributions, #ad isn’t enough, HRA now regulates trial recruitment (from 1 Feb 2026), and signposting plus a risk-based misinformation plan are essential. Audit headlines, retrain teams, update contracts
